SMC approves belzutifan for VHL kidney cancer in Scotland
We are delighted to announce that the Scottish Medicines Consortium [...]
Pembrolizumab plus lenvatinib for non-clear cell kidney cancer
Immunotherapy combinations are becoming the standard treatment for people with [...]
Belzutifan significantly delays progression of advanced kidney cancer after other treatments have failed
Kidney cancers often have mutations in a gene called the von Hippel-Lindau [...]
Corticosteroids during treatment with nivolumab may not affect survival in kidney cancer
A recent study published in the journal JAMA Oncology has [...]
How long side effects last after treatment with axitinib is stopped
Axitinib is a medicine for the treatment of advanced kidney [...]
Pembrolizumab plus lenvatinib as first-line treatment for advanced non-clear cell kidney cancer
Immunotherapy combinations are becoming the standard treatment after surgery for [...]
Tivozanib for heavily pre-treated patients with advanced kidney cancer
TIVO-3 was a phase 3 clinical trial that compared tivozanib, [...]
Adjuvant therapy for kidney cancer
Adjuvant therapy aims to reduce the risk of the cancer [...]
Hormonal immune-related side effects to immunotherapies
This study looked at the incidence, diagnosis and treatment of [...]
Four-year follow-up with lenvatinib plus pembrolizumab for advanced kidney cancer
Further follow-up data from the phase 3 CLEAR study with [...]
